To evaluate the clinical relevance of our preclinical findings, we analyzed two publicly available gene expression datasets (GSE75299 and GSE50535) comprising matched tumor biopsies from melanoma patients collected before, during, and after treatment with BRAF inhibitors (BRAFi) or combined BRAF/MEK inhibitors (BRAF/MEKi) (Table S2, Supporting Information).[17, 18] These datasets provided an opportunity to evaluate dynamic changes in ECM‐related gene expression in response to targeted therapy. This evidence concerns the gene MAP2K7 and neoplasm.